Prevalence of genital high-risk human papillomavirus infections and associated factors among women living with human immunodeficiency virus in Uganda

• Published in: BMC cancer Vol. 24; no. 1; p. 243
• Main Authors: Nakigozi, Harriet, Ndejjo, Rawlance, Bazeyo, William, Nabaggala, Annet, Achola, Caroline, Iga, Moses, Kalyesubula, Simeon, Kanamwangi, Ben, Mutungi, Gerald, Batte, Charles, Mukunya, David, Sserwanga, Lawrence, Gemageine, Godfrey, Oyoo, Charles Akiya, Nabadda, Susan
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21-02-2024; BioMed Central; BMC
• Subjects: Analysis; Antiretroviral therapy; Antiviral agents; Cancer screening; Care and treatment; Cervical Cancer; Cervical Cancer screening; Complications and side effects; Disease prevention; Dosage and administration; Drug therapy; Genetic testing; Genotypes; Health facilities; HIV; Hologic; Hospitals; HPV Aptima; Human immunodeficiency virus; Human immunodeficiency virus (HIV); Human papillomavirus; Human papillomavirus (HPV); Immune system; Infections; Laboratories; Medical screening; Mortality; Papillomavirus infections; Prevalence studies (Epidemiology); Prevention; Public health; Questionnaires; Regions; Risk factors; Sample size; Vagina; Womens health; Uganda; Panther; Cervical Cancer; Cervical Cancer screening; Hologic; HPV Aptima; Human papillomavirus (HPV); Preservecyt solution; Human immunodeficiency virus (HIV)
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-024-11928-0

Women living with HIV are at risk for cervical dysplasia and cancer worldwide. In 2015, the World Health Organization (WHO) recommended that testing for high-risk HPV (hrHPV) infection be incorporated into cervical cancer screening programs using molecular nucleic acid tests (NATs) but this has not previously been done in Uganda. The country's coverage for Human Papilloma Virus (HPV) screening remains low at less than 10% for women aged 25-49 years. This study determined the genital prevalence of hrHPV infection and the associated factors among women living with HIV in Uganda.
A descriptive cross-sectional study was conducted in 15 selected health facilities among participants who were on Antiretroviral therapy (ART). Participants who consented to participate were instructed on how to collect their own high vaginal swabs using a cervical brush for HPV molecular testing (HPV DNA or HPV RNA) and their demographics data was collected using a standard questionnaire. Laboratory diagnosis for HPV molecular testing was done using Gene xpert machines and Hologic Aptima Machine. Modified Poisson regression analysis was conducted to determine the associated factors.
This study involved 5856 HIV positive participants on ART. A total of 2006 out of 5856 (34.3%) participants had high risk HPV infections. HPV infections by genotypes were: HPV16 317(15.8%), HPV 18/45 308 (15.4%) and other high-risk HPV 1381 (68.8%). The independent factors associated with all hrHPV were parity, education level, having more than one partner, and engaging in early sex. Smoking was associated with HPV 16, HPV 18/45 and other hrHPV. Age was associated with all hrHPV, marital status with HPV 16, and occupation with HPV 16.
The prevalence of genital high-risk HPV infections among HIV positive women attending ART clinics in public facilities in Uganda was high. Other hrHPV genotype was the commonest compared to 18/45 and HPV 16. The integration of cervical cancer screening in ART programmes remains paramount to support the early detection of cervical cancer and Non-invasive self-collected urine and vaginal sampling for cervical cancer screening present an opportunity.